Texas judge orders FDA to accelerate release of COVID-19 vaccine trial data (which the FDA tried to delay for 75 years)
A federal judge in Texas has ordered the
Food and Drug Administration (FDA) to
accelerate the release Wuhan coronavirus (COVID-19) vaccine trial data.
The
four-page decision of District Judge Mark Pittman ordered FDA to produce the data on Moderna's vaccine for adults and Pfizer's vaccine for children about 10 times faster than the agency wanted, or at an average rate of at least 180,000 pages per month.
In January 2022, Pittman also forced the FDA to produce all its data on Pfizer's coronavirus shots for those aged 16 and older at a rate of 55,000 pages per month, or much faster than the 75 years the agency had sought.
The recent order required the federal agency to produce all of its data on Pfizer's COVID-19 injection for 12- to 15-year-olds and Moderna's COVID-19 injection for adults by June 31, 2025. The FDA wanted to release the estimated 4.8 million pages at 1,000 to 16,000 pages per month, which would have taken more than 23 years. The
lawsuit was filed against the agency by Aaron Siri of Siri & Glimstad, who is representing the parents of a child injured by COVID-19 vaccine.
While the judge noted in his order that the court recognizes the FDA's limited resources dedicated to freedom of information requests (FOIA), he stated that "the number of resources an agency dedicates to such requests does not dictate the bounds of an individual's FOIA rights."
"Instead, the Court must ensure that the fullest possible disclosure of the information sought is timely provided – as 'stale information is of little value,'" Pittman wrote. (Related:
Pfizer trial data reveal that vaccinated people are 400% more likely to die from fatal cardiac arrest.)
FDA rushed approval of COVID-19 vaccines
Meanwhile, Republicans on the House Select Subcommittee on the Coronavirus Pandemic recently announced that they were seeking answers after newly discovered emails indicate that the
FDA rushed the approval of COVID-19 vaccines and boosters to accommodate vaccine mandates.
Per the correspondence, Pfizer asked the FDA in May 2021 to approve their vaccine. Regulators publicly said that the review of the "Biologics License Application" would likely be done by January 2022, but behind the scenes, top agency officials were pushing the Office of Vaccines Research and Review (OVRR) to quickly complete the review.
The
Epoch Times reported that Dr. Marion Gruber, the head of the OVRR at the time, and her deputy Dr. Phil Krause outlined in a memorandum that the review could not be done before September 15, 2021. "OVRR believes that public confidence in COVID-19 vaccines would not be served by rushing our review and evaluation of the submitted data," Gruber wrote in an email to Dr. Janet Woodcock, the acting FDA commissioner at the time, and Dr. Peter Marks, another top official at the agency.
Still, the FDA proceeded to approve Pfizer's COVID-19 vaccine on August 23, 2021.
Dr. Robert Malone, the inventor of the messenger RNA (mRNA) technology that Pfizer's vaccine uses, told the
Epoch Times: "Previously, one could infer that there was a coupling between regulatory decisions and political expediency. But with these emails, you see the smoking gun."
Check out
PharmaceuticalFraud.com for more news on Big Pharma's dangerous vaccines.
Watch the video below where Dr. Naomi Wolf talks about
bombshell Pfizer data and how the FDA attempted to censor it for 75 years.
This video is from
PJ Glassey's channel on Brighteon.com.
More related stories:
Pfizer found to have covered up injuries and deaths of study participants in their clinical covid-19 vaccine trials.
Pfizer is terrified of discovery in Brook Jackson's legal case against the company – "Pfizer lied. People died," says attorney.
Pfizer is terrified of discovery in Brook Jackson's legal case against the company – "Pfizer lied. People died", says attorney.
Report: FDA's failure to adequately oversee vaccine clinical trials is endangering public health.
Sources include:
TheEpochTimes.com
FingFX.ThomsonReuters.com
SiriLLP.com
DocumentCloud.org
Brighteon.com